Brokerages Anticipate Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) Will Post Earnings of -$0.47 Per Share

Wall Street brokerages expect Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) to announce earnings per share (EPS) of ($0.47) for the current quarter, Zacks reports. Zero analysts have provided estimates for Cyclacel Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.50) and the highest estimate coming in at ($0.43). Cyclacel Pharmaceuticals posted earnings of ($3.20) per share during the same quarter last year, which would indicate a positive year over year growth rate of 85.3%. The firm is expected to announce its next quarterly earnings results on Tuesday, August 11th.

On average, analysts expect that Cyclacel Pharmaceuticals will report full year earnings of ($2.54) per share for the current financial year, with EPS estimates ranging from ($3.12) to ($1.96). For the next year, analysts forecast that the company will post earnings of ($1.83) per share, with EPS estimates ranging from ($2.14) to ($1.42). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that follow Cyclacel Pharmaceuticals.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its quarterly earnings results on Tuesday, May 12th. The biotechnology company reported ($1.48) EPS for the quarter, topping analysts’ consensus estimates of ($2.90) by $1.42.

Several research analysts recently weighed in on CYCC shares. LADENBURG THALM/SH SH reaffirmed a “buy” rating and issued a $18.00 target price on shares of Cyclacel Pharmaceuticals in a report on Thursday, May 21st. Brookline Capital Management began coverage on Cyclacel Pharmaceuticals in a report on Tuesday, May 19th. They set a “buy” rating and a $22.00 price target on the stock. Zacks Investment Research raised Cyclacel Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research report on Thursday, May 7th. Roth Capital reaffirmed a “buy” rating and issued a $24.00 price objective on shares of Cyclacel Pharmaceuticals in a research note on Thursday, May 21st. Finally, ValuEngine raised shares of Cyclacel Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 17th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $17.13.

A hedge fund recently raised its stake in Cyclacel Pharmaceuticals stock. Renaissance Technologies LLC boosted its holdings in shares of Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) by 8.4% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,269,326 shares of the biotechnology company’s stock after buying an additional 98,364 shares during the period. Renaissance Technologies LLC owned approximately 7.38% of Cyclacel Pharmaceuticals worth $850,000 as of its most recent SEC filing. Institutional investors and hedge funds own 33.69% of the company’s stock.

Cyclacel Pharmaceuticals stock traded up $0.02 during mid-day trading on Wednesday, hitting $4.56. The company’s stock had a trading volume of 3,558 shares, compared to its average volume of 299,029. The company has a debt-to-equity ratio of 0.10, a current ratio of 7.76 and a quick ratio of 7.76. Cyclacel Pharmaceuticals has a 12 month low of $3.85 and a 12 month high of $19.60. The stock has a market cap of $22.16 million, a price-to-earnings ratio of -0.49 and a beta of 1.24. The business has a 50 day moving average price of $4.71 and a 200-day moving average price of $2.08.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's oncology development programs include CYC065, a cyclin dependent kinase Inhibitors (CDK) that is in Phase I clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase I clinical trial for the treatment of advanced leukemias.

Featured Article: SEC Filing

Get a free copy of the Zacks research report on Cyclacel Pharmaceuticals (CYCC)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Cyclacel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclacel Pharmaceuticals and related companies with's FREE daily email newsletter.